We have great news today as Omixon Biocomputing and Knome has become partners to offer advanced HLA typing for whole genome and exome level data. We believe that this partnership will help us “discover safer and more efficient therapies by identifying genomic biomarkers for drug response and adverse response,” as our CEO, Attila Berces, described.

GenomeWeb also covered this important announcement:

Knome has announced that its services division will now offer Omixon”s targeted human leukocyte antigen typing capabilities as part of its whole genome and exome interpretation pipelines.

 

Omixon CEO Attila Berces said in a statement that the HLA typing service should help pharmaceutical companies that utilize Knome”s services to identify drug response biomarkers, “shorten the time to approval, and reduce the risk of late-stage failures.”